ArticleGut2005
Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors.
Article in Gut, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 103 citations in OpenAlex.
- Labour and premature delivery differentially affect the expression of the endocannabinoid system in the human placenta.Histochemistry and cell biology · 2023Article
- Hepatic targeting of the centrally active cannabinoid 1 receptor (CBJournal of controlled release : official journal of the Controlled Release Society · 2023Article
- The Enteric Glia and Its Modulation by the Endocannabinoid System, a New Target for Cannabinoid-Based Nutraceuticals?Molecules (Basel, Switzerland) · 2022Review
- Hepatorenal syndrome in children: a review.Pediatric nephrology (Berlin, Germany) · 2021Review
- CaSR participates in the regulation of vascular tension in the mesentery of hypertensive rats via the PLC‑IP3/AC‑V/cAMP/RAS pathway.Molecular medicine reports · 2019Article
- Roles of the Hepatic Endocannabinoid and Apelin Systems in the Pathogenesis of Liver Fibrosis.Cells · 2019Review
- Endocannabinoid System in Hepatic Glucose Metabolism, Fatty Liver Disease, and Cirrhosis.International journal of molecular sciences · 2019Review
- Cannabinoids in arterial, pulmonary and portal hypertension - mechanisms of action and potential therapeutic significance.British journal of pharmacology · 2019Review
- The endocannabinoid anandamide causes endothelium-dependent vasorelaxation in human mesenteric arteries.Pharmacological research · 2016Article
- MicroRNAs in liver cancer: a model for investigating pathogenesis and novel therapeutic approaches.Cell death and differentiation · 2015Review
- Cirrhotic cardiomyopathy: a cardiologist's perspective.World journal of gastroenterology · 2014Review
- Effect of chirality and lipophilicity in the functional activity of evodiamine and its analogues at TRPV1 channels.British journal of pharmacology · 2014Article
- Splanchnic vasodilation and hyperdynamic circulatory syndrome in cirrhosis.World journal of gastroenterology · 2014Review
- Vascular targets for cannabinoids: animal and human studies.British journal of pharmacology · 2014Review
- Why do cannabinoid receptors have more than one endogenous ligand?Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2012Review
- Endocannabinoids in liver disease.Hepatology (Baltimore, Md.) · 2011Review
- Spontaneous bacterial peritonitis: from pathophysiology to prevention.Internal and emergency medicine · 2010Review
- Physiopathology of splanchnic vasodilation in portal hypertension.World journal of hepatology · 2010Article
- Endocannabinoids and cardiac contractile function: pathophysiological implications.Pharmacological research · 2009Review
- Prejunctional and peripheral effects of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).Naunyn-Schmiedeberg's archives of pharmacology · 2008Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsAnandamide is an endocannabinoid that evokes hypotension by interaction with peripheral cannabinoid CB1 receptors and with the perivascular transient receptor potential vanilloid type 1 protein (TRPV1). As anandamide has been implicated in the vasodilated state in advanced cirrhosis, the study investigated whether the mesenteric bed from cirrhotic rats has an altered and selective vasodilator response to anandamide.
methodsWe assessed vascular sensitivity to anandamide, mRNA and protein expression of cannabinoid CB1 receptor and TRPV1 receptor, and the topographical distribution of cannabinoid CB1 receptors in resistance mesenteric arteries of cirrhotic and control rats.
resultsMesenteric vessels of cirrhotic animals displayed greater sensitivity to anandamide than control vessels. This vasodilator response was reverted by CB1 or TRPV1 receptor blockade, but not after endothelium denudation or nitric oxide inhibition. Anandamide had no effect on distal femoral arteries. CB1 and TRPV1 receptor protein was higher in cirrhotic than in control vessels. Neither CB1 mRNA nor protein was detected in femoral arteries. Immunochemistry showed that CB1 receptors were mainly in the adventitia and in the endothelial monolayer, with higher expression observed in vessels of cirrhotic rats than in controls.
conclusionsThese results indicate that anandamide is a selective splanchnic vasodilator in cirrhosis which predominantly acts via interaction with two different types of receptors, CB1 and TRPV1 receptors, which are mainly located in perivascular sensory nerve terminals of the mesenteric resistance arteries of these animals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.